SQ Ami is a game changer simplifying delivery of Amivamtamab, reducing health care burden and is preferred by patients with 5 fold reduction in infusion related reactions #paloma3 #WCLC24 MUSC Hollings Cancer Center MUSC Health

Ready for an amazing #ESMO2024 - if the data are as beautiful as this sunrise, it’s great news for patients!

The U.S. FDA approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. This milestone marks J&J Innovative Medicine’s third new indication in six months for this targeted therapy: bit.ly/4dfTihQ

#NEWS: The U.S. FDA has approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. Learn more here: jnj.com/media-center/p… #JNJOncology

Getting #InFrontofCancer means recognizing the current standard of care is not enough for our patients – they deserve more. This #LungCancerAwarenessMonth, I’m honored to share what drives my passion to get in front of this disease: bit.ly/4dnT4G1

Exciting progress for patients in Europe! A CHMP positive opinion brings us closer to offering the first chemotherapy-free combination therapy for first-line treatment of EGFRm #NSCLC. Proud to be part of the journey to redefine standards of care. bit.ly/3Z5rGrY

Excited to announce the European Commission approved our chemotherapy-free combination therapy for the first-line treatment of EGFRm #NSCLC. Proud to be part of a team at #JNJOncology that continues to drive innovation for patients. bit.ly/4gz7u8k

🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀 jnj.com/media-center/p…

Update on #Mariposa study for #EGFR #NSCLC from Johnson & Johnson Innovation. Providing more hope for patients. #MyCompany prnewswire.com/news-releases/…

Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce J&J Innovative Medicine’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: bit.ly/4a3Dwa9

Today, we’re one step closer to transforming care for EGFRm #NSCLC. I’m excited to share that the European Commission has now fully approved our chemo-free regimen—a breakthrough that offers a new way forward for patients and their families across the EU: bit.ly/3E3RBbC

Exciting news in Europe! The CHMP recommends our subcutaneous therapy for patients with advanced #NSCLC with certain EGFR mutations. Read about this potential new option that can improve the treatment experience for patients: bit.ly/3Q0V5OH

Every step forward brings new hope for patients and their families. Together, we’re working to change what’s possible in lung cancer care: bit.ly/4hR7PTN #MyCompany #JNJOncology #ELCC2025

Proud to share my latest podcast episode. Meet Joshua Bauml, MD He has great story & doing great work for the cancer community J&J Innovative Medicine Mark Wildgust (he/him) Ania DiAntonio Brian Kenney Rebecca Genin Rita Ribeiro Caroline Pavis Jackie Zima-Evans #lungcancer #cancerresearch tinyurl.com/mr3skrcf

Looking forward to sharing the story of how the J&J Innovative Medicine team working in partnership with the medical community Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 marivi mateos Byoung Chul Cho, M.D., Ph.D. has been at the forefront of innovation in developing bispecifics in oncology. Register to join. #MyCompany …ngbispecificantibodies.splashthat.com

My favorite way to start my conference every year. So excited to see all the new data presented and so many friends at #ASCO2025

Great to see Jill Feldman present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At J&J Innovative Medicine we work collaboratively with all in the medical community to advance care for patients. #MyCompany

Grateful to Johnson & Johnson Innovation for the opportunity to be the lead author on #COCOON trial #PRO data at #ASCO25. It meant a lot to be a co-investigator and true partner and help shape the secondary endpoint to measure what matters to patients (#QOL matters)! #LCSM

As #ASCO25 draws to a close I am leaving Chicago inspired by the amazing work being done by researchers to help patients with cancer around the world. This is truly one of the #BreathtakingMoments of working in oncology. Until next time ASCO!

Lung cancer remains one of the toughest cancers to treat, but research is helping shift what’s possible. This #WorldLungCancerDay, I’m reflecting on how far science has come and how much more we still need to do for people with this disease: bit.ly/4nrHPlN #JNJOncology